Key information

🔎 Fund Overview

Covance Inc., a drug development services company, provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries worldwide. It operates in two segments, Early Development and Late-Stage Development. The Early Development segment offers preclinical services, such as toxicology, pharmaceutical chemistry, nutritional chemistry and food safety, purpose-bred animals for biomedical research, lead optimization and translational services, and bioanalytical testing services. This segment also provides clinical pharmacology services, including first-in-human trials and early patient proof of concept studies of new pharmaceuticals at its clinics in the United States and the United Kingdom. The Late-Stage Development segment offers central laboratory services to biotechnology and pharmaceutical customers; and clinical development services, such as the full management of Phase II through IV clinical studies, study design and modeling, co-ordination of study activities, trial logistics, monitoring of study site performance, clinical data management and biostatistical analysis, and medical writing and regulatory services, as well as periapproval services. This segment also provides market access services, including reimbursement and healthcare economics consulting services, which comprise outcomes and pharmacoeconomic studies, reimbursement planning, reimbursement advocacy programs, risk evaluation and mitigation strategy services, registry services, specialty pharmacy services, and managed market contracting services; and clinical trial support services, such as interactive voice and Web response, and cardiac safety services. The company also provides laboratory testing services to the chemical, agrochemical, and food industries. Covance Inc. was founded in 1987 and is headquartered in Princeton, New Jersey. Covance Inc. (NYSE:CVD) operates independently of Corning Inc. as of December 31, 1996.